298 related articles for article (PubMed ID: 26569500)
41. Early effects of low dose bevacizumab treatment assessed by magnetic resonance imaging.
Gaustad JV; Simonsen TG; Smistad R; Wegner CS; Andersen LM; Rofstad EK
BMC Cancer; 2015 Nov; 15():900. PubMed ID: 26573613
[TBL] [Abstract][Full Text] [Related]
42. Immuno-PET Imaging of HER3 in a Model in which HER3 Signaling Plays a Critical Role.
Yuan Q; Furukawa T; Tashiro T; Okita K; Jin ZH; Aung W; Sugyo A; Nagatsu K; Endo H; Tsuji AB; Zhang MR; Masuko T; Inoue M; Fujibayashi Y; Saga T
PLoS One; 2015; 10(11):e0143076. PubMed ID: 26571416
[TBL] [Abstract][Full Text] [Related]
43. Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer.
Russo M; Siravegna G; Blaszkowsky LS; Corti G; Crisafulli G; Ahronian LG; Mussolin B; Kwak EL; Buscarino M; Lazzari L; Valtorta E; Truini M; Jessop NA; Robinson HE; Hong TS; Mino-Kenudson M; Di Nicolantonio F; Thabet A; Sartore-Bianchi A; Siena S; Iafrate AJ; Bardelli A; Corcoran RB
Cancer Discov; 2016 Feb; 6(2):147-153. PubMed ID: 26644315
[TBL] [Abstract][Full Text] [Related]
44. Prevalence of KRAS, BRAF, PI3K and EGFR mutations among Asian patients with metastatic colorectal cancer.
Phua LC; Ng HW; Yeo AH; Chen E; Lo MS; Cheah PY; Chan EC; Koh PK; Ho HK
Oncol Lett; 2015 Oct; 10(4):2519-2526. PubMed ID: 26622882
[TBL] [Abstract][Full Text] [Related]
45. A plasma cytokine and angiogenic factor (CAF) analysis for selection of bevacizumab therapy in patients with metastatic colorectal cancer.
Bai L; Wang F; Zhang DS; Li C; Jin Y; Wang DS; Chen DL; Qiu MZ; Luo HY; Wang ZQ; Li YH; Wang FH; Xu RH
Sci Rep; 2015 Dec; 5():17717. PubMed ID: 26620439
[TBL] [Abstract][Full Text] [Related]
46. Does the addition of drugs targeting the vascular endothelial growth factor pathway to first-line chemotherapy increase complete response? A meta-analysis of randomized clinical trials.
Li Y; Liang XY; Yue YQ; Sheng L; Liu JK; Wang ZY; Chen G
Tumour Biol; 2016 May; 37(5):6297-306. PubMed ID: 26619847
[TBL] [Abstract][Full Text] [Related]
47. KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib.
Nilsson MB; Giri U; Gudikote J; Tang X; Lu W; Tran H; Fan Y; Koo A; Diao L; Tong P; Wang J; Herbst R; Johnson BE; Ryan A; Webster A; Rowe P; Wistuba II; Heymach JV
Clin Cancer Res; 2016 Apr; 22(8):1940-50. PubMed ID: 26578684
[TBL] [Abstract][Full Text] [Related]
48. The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer--a systematic review.
Mendes D; Alves C; Afonso N; Cardoso F; Passos-Coelho JL; Costa L; Andrade S; Batel-Marques F
Breast Cancer Res; 2015 Nov; 17():140. PubMed ID: 26578067
[TBL] [Abstract][Full Text] [Related]
49. RAS testing in metastatic colorectal cancer: advances in Europe.
Van Krieken JH; Rouleau E; Ligtenberg MJ; Normanno N; Patterson SD; Jung A
Virchows Arch; 2016 Apr; 468(4):383-96. PubMed ID: 26573425
[TBL] [Abstract][Full Text] [Related]
50. A single-arm Phase II validation study of preventing oxaliplatin-induced hypersensitivity reactions by dexamethasone: the AVOID trial.
Yoshida Y; Hirata K; Matsuoka H; Iwamoto S; Kotaka M; Fujita H; Aisu N; Hoshino S; Kosaka T; Maeda K; Kiyomi F; Yamashita Y
Drug Des Devel Ther; 2015; 9():6067-73. PubMed ID: 26648694
[TBL] [Abstract][Full Text] [Related]
51. Significant effect of VEGFA polymorphisms on the clinical outcome of metastatic colorectal cancer patients treated with FOLFIRI-cetuximab.
Rollin J; Payancé A; Gouilleux-Gruart V; Boisdron-Celle M; Azzopardi N; Morel A; Gruel Y; Paintaud G; Gamelin E; Watier H; Lecomte T
Pharmacogenomics; 2015 Dec; 16(18):2035-43. PubMed ID: 26615857
[TBL] [Abstract][Full Text] [Related]
52. Exploiting HPV-Induced Carcinogenesis for a Rational Drug Development in Cervical Cancer.
Nogueira-Rodrigues A; Melo AC; Werutsky G; Garces AH; Ferreira CG
Curr Cancer Drug Targets; 2016; 16(3):249-60. PubMed ID: 26577537
[TBL] [Abstract][Full Text] [Related]
53. Survival Benefit of Exercise Differs by Tumor IRS1 Expression Status in Colorectal Cancer.
Hanyuda A; Kim SA; Martinez-Fernandez A; Qian ZR; Yamauchi M; Nishihara R; Morikawa T; Liao X; Inamura K; Mima K; Cao Y; Zhang X; Wu K; Chan AT; Giovannucci EL; Meyerhardt JA; Fuchs CS; Shivdasani RA; Ogino S
Ann Surg Oncol; 2016 Mar; 23(3):908-17. PubMed ID: 26577117
[TBL] [Abstract][Full Text] [Related]
54. G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab.
Fiala O; Buchler T; Mohelnikova-Duchonova B; Melichar B; Matejka VM; Holubec L; Kulhankova J; Bortlicek Z; Bartouskova M; Liska V; Topolcan O; Sedivcova M; Finek J
Tumour Biol; 2016 May; 37(5):6823-30. PubMed ID: 26662311
[TBL] [Abstract][Full Text] [Related]
55. Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study.
Meulendijks D; Beerepoot LV; Boot H; de Groot JW; Los M; Boers JE; Vanhoutvin SA; Polee MB; Beeker A; Portielje JE; de Jong RS; Goey SH; Kuiper M; Sikorska K; Beijnen JH; Tesselaar ME; Schellens JH; Cats A
Invest New Drugs; 2016 Feb; 34(1):119-28. PubMed ID: 26643663
[TBL] [Abstract][Full Text] [Related]
56. [Analysis of Factors Influencing the Development of Hypomagnesemia in Patients Receiving Cetuximab Therapy for Head and Neck Cancer].
Inose R; Takahashi K; Nishikawa T; Nagayama K
Yakugaku Zasshi; 2015; 135(12):1403-7. PubMed ID: 26632157
[TBL] [Abstract][Full Text] [Related]
57. Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC).
Hall RD; Le TM; Haggstrom DE; Gentzler RD
Transl Lung Cancer Res; 2015 Oct; 4(5):515-23. PubMed ID: 26629420
[TBL] [Abstract][Full Text] [Related]
58. Afatinib-based combination regimens for the treatment of solid tumors: rationale, emerging strategies and recent progress.
Bennouna J; Moreno Vera SR
Future Oncol; 2016 Feb; 12(3):355-72. PubMed ID: 26603212
[TBL] [Abstract][Full Text] [Related]
59. Dysphonia after Bevacizumab Rechallenge: A Case Report.
Carter CA; Caroen SZ; Oronsky AL; Oronsky BT
Case Rep Oncol; 2015; 8(3):423-5. PubMed ID: 26600773
[TBL] [Abstract][Full Text] [Related]
60. Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer.
Leon O; Guren MG; Radu C; Gunnlaugsson A; Johnsson A
Eur J Cancer; 2015 Dec; 51(18):2740-6. PubMed ID: 26597443
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
